hPSCreg®
This website uses cookies to keep track of login sessions and for internal Matomo Statistics. See our Privacy Policy for details. This website uses cookies, learn more


GENYOi006-A-1

Registration Summary:

GRX-MCiPS4F-A2-ETO2-GLIS2

GENYOi006-A-1

General#

Cell Line
hPSCreg Name GENYOi006-A-1
Alternative name(s)
GRX-MCiPS4F-A2-ETO2-GLIS2
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 15th June 2020
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider
Generator Centre for Genomics and Oncological Research (GENYO)
Owner Centre for Genomics and Oncological Research (GENYO)
Derivation country Spain

External Databases
BioSamples SAMEA6438547
Cellosaurus CVCL_YN83
CLO CLO_0102823

General Information
* Is the cell line readily obtainable for third parties?
No
Subclone of

Donor Information#

General Donor Information
Sex male
Ethnicity Spaniard Caucasian

Phenotype and Disease related information (Donor)
Diseases No disease was diagnosed.

Karyotyping (Donor)
Has the donor karyotype been analysed?
Yes
46, xy
Karyotyping method: G-Banding

Other Genotyping (Donor)
Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)
BioSamples SAMEA6438546

Ethics#

Also have a look at the ethics information for the parental line GENYOi006-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Dr. Tanja Gruber (Memphis, USA)

hIPSC Derivation#

General
The source cell information can be found in the parental cell line GENYOi006-A.

Reprogramming method
Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Other
Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions#

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
NANOG
Yes
SOX2
Yes
SSEA-3
Yes
SSEA-4
Yes
TRA 1-60
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
CDX2
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
WT1
Unknown
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
Nestin
Unknown

Microbiology / Virus Screening
Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)
Has the cell line karyotype been analysed?
Yes
46, xy
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification#

Disease/phenotype related modifications
Acute myeloid leukemia
Acute myeloid leukemia in the OLS
Synonyms
  • AML
  • Acute myelogenous leukemia
  • Acute myeloblastic leukemia
  • Acute myelocytic leukemia
  • Acute myeloid leukaemia
show more synonyms
Genetic modifications
ETO2-GLIS2 (target)
Transgene expression
inv16
The cell line GENYOi006-A-1 was generated by lentiviral transduction of the cell line GENYOi006-A for the expression of the transgene ETO2-GLIS2 (CBFA2T3-GLIS2). In patients, the transgene ETO2-GLIS2 is generated by inversion of chromosome 16 (inv16). The transgene ETO2-GLIS2 from a patient with acute myeloid leukemia were subcloned in a lentiviral vector and was used for lentiviral particles generation.
Viral
Lentivirus